Marfan's syndrome is an autosomal dominant condition with an estimated 
prevalence of one in 10,000 to 20,000 individuals. This rare hereditary 
connective tissue disorder affects many parts of the body. The diagnosis of 
Marfan's syndrome is established in accordance with a review of the diagnostic 
criteria, known as the Ghent nosology, through a comprehensive assessment 
largely based on a combination of major and minor clinical manifestations in 
various organ systems and the family history. Aortic root dilation and mitral 
valve prolapse are the main presentations among the cardiovascular malformations 
of Marfan's syndrome. The pathogenesis of Marfan's syndrome has not been fully 
elucidated. However, fibrillin-1 gene mutations are believed to exert a dominant 
negative effect. Therefore, Marfan's syndrome is termed a fibrillinopathy, along 
with other connective tissue disorders with subtle differences in clinical 
manifestations. The treatment may include prophylactic β-blockers and 
angiotensin II-receptor blockers in order to slow down the dilation of the 
ascending aorta, and prophylactic aortic surgery. Importantly, β-blocker therapy 
may reduce TGF-β activation, which has been recognized as a contributory factor 
in Marfan's syndrome. The present article aims to provide an overview of this 
rare hereditary disorder.